Paul Bastard

InstitutionUniversity of Paris
AddressParis
France
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 23 Covid-19 publications, with a maximum of 8 publications in August 2021
    All Publications
    Bar chart showing 26 publications over 3 distinct years, with a maximum of 20 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Citations: 10     Fields:    Translation:Humans
    2. Lopez J, Mommert M, Mouton W, Pizzorno A, Brengel-Pesce K, Mezidi M, Villard M, Lina B, Richard JC, Fassier JB, Cheynet V, Padey B, Duliere V, Julien T, Paul S, Bastard P, Belot A, Bal A, Casanova JL, Rosa-Calatrava M, Morfin F, Walzer T, Trouillet-Assant S. Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med. 2021 Oct 04; 218(10). PMID: 34415984.
      Citations: 1     Fields:    
    3. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 08 19; 6(62). PMID: 34413139.
      Citations: 28     Fields:    Translation:Humans
    4. Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, Zhang P, Meertens L, Bolze A, Materna M, Korniotis S, Gervais A, Talouarn E, Bigio B, Seeleuthner Y, Bilguvar K, Zhang Y, Neehus AL, Ogishi M, Pelham SJ, Le Voyer T, Rosain J, Philippot Q, Soler-Palacín P, Colobran R, Martin-Nalda A, Rivière JG, Tandjaoui-Lambiotte Y, Chaïbi K, Shahrooei M, Darazam IA, Olyaei NA, Mansouri D, Hatipoglu N, Palabiyik F, Ozcelik T, Novelli G, Novelli A, Casari G, Aiuti A, Carrera P, Bondesan S, Barzaghi F, Rovere-Querini P, Tresoldi C, Franco JL, Rojas J, Reyes LF, Bustos IG, Arias AA, Morelle G, Christèle K, Troya J, Planas-Serra L, Schlüter A, Gut M, Pujol A, Allende LM, Rodriguez-Gallego C, Flores C, Cabrera-Marante O, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021 08 19; 6(62). PMID: 34413140.
      Citations: 21     Fields:    Translation:Humans
    5. Goncalves D, Mezidi M, Bastard P, Perret M, Saker K, Fabien N, Pescarmona R, Lombard C, Walzer T, Casanova JL, Belot A, Richard JC, Trouillet-Assant S. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunology. 2021; 10(8):e1327. PMID: 34429968.
      Citations: 8     
    6. Abers MS, Rosen LB, Delmonte OM, Shaw E, Bastard P, Imberti L, Quaresima V, Biondi A, Bonfanti P, Castagnoli R, Casanova JL, Su HC, Notarangelo LD, Holland SM, Lionakis MS. Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol Cell Biol. 2021 10; 99(9):917-921. PMID: 34309902.
      Citations: 6     Fields:    Translation:Humans
    7. Lopez J, Mommert M, Mouton W, Pizzorno A, Brengel-Pesce K, Mezidi M, Villard M, Lina B, Richard JC, Fassier JB, Cheynet V, Padey B, Duliere V, Julien T, Paul S, Bastard P, Belot A, Bal A, Casanova JL, Rosa-Calatrava M, Morfin F, Walzer T, Trouillet-Assant S. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med. 2021 10 04; 218(10). PMID: 34357402.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    8. Zhang Q, Cobat A, Bastard P, Notarangelo LD, Su HC, Abel L, Casanova JL. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. J Clin Invest. 2021 08 02; 131(15). PMID: 34166232.
      Citations: 3     Fields:    Translation:Humans
    9. Bastard P, Orlova E, Sozaeva L, Lévy R, James A, Schmitt MM, Ochoa S, Kareva M, Rodina Y, Gervais A, Le Voyer T, Rosain J, Philippot Q, Neehus AL, Shaw E, Migaud M, Bizien L, Ekwall O, Berg S, Beccuti G, Ghizzoni L, Thiriez G, Pavot A, Goujard C, Frémond ML, Carter E, Rothenbuhler A, Linglart A, Mignot B, Comte A, Cheikh N, Hermine O, Breivik L, Husebye ES, Humbert S, Rohrlich P, Coaquette A, Vuoto F, Faure K, Mahlaoui N, Kotnik P, Battelino T, Trebušak Podkrajšek K, Kisand K, Ferré EMN, DiMaggio T, Rosen LB, Burbelo PD, McIntyre M, Kann NY, Shcherbina A, Pavlova M, Kolodkina A, Holland SM, Zhang SY, Crow YJ, Notarangelo LD, Su HC, Abel L, Anderson MS, Jouanguy E, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021 07 05; 218(7). PMID: 33890986.
      Citations: 22     Fields:    Translation:Humans
    10. Bastard P, Zhang Q, Cobat A, Jouanguy E, Zhang SY, Abel L, Casanova JL. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia. C R Biol. 2021 Jun 21; 344(1):19-25. PMID: 34213846.
      Citations: 2     Fields:    Translation:Humans
    11. Vinh DC, Abel L, Bastard P, Cheng MP, Condino-Neto A, Gregersen PK, Haerynck F, Cicalese MP, Hagin D, Soler-Palacín P, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova JL, Meyts I. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-ß. J Clin Immunol. 2021 10; 41(7):1425-1442. PMID: 34101091.
      Citations: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    12. Malle L, Bastard P, Martin-Nalda A, Carpenter T, Bush D, Patel R, Colobran R, Soler-Palacin P, Casanova JL, Gans M, Rivière JG, Bogunovic D. Atypical Inflammatory Syndrome Triggered by SARS-CoV-2 in Infants with Down Syndrome. J Clin Immunol. 2021 10; 41(7):1457-1462. PMID: 34089457.
      Citations: 2     Fields:    Translation:Humans
    13. Citations: 7     Fields:    Translation:HumansCells
    14. Vazquez SE, Bastard P, Kelly K, Gervais A, Norris PJ, Dumont LJ, Casanova JL, Anderson MS, DeRisi JL. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. J Clin Immunol. 2021 08; 41(6):1169-1171. PMID: 34009544.
      Citations: 8     Fields:    Translation:Humans
    15. Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021 06; 47(6):704-706. PMID: 33835207.
      Citations: 15     Fields:    Translation:Humans
    16. Citations: 22     Fields:    Translation:HumansCells
    17. Bastard P, Lévy R, Henriquez S, Bodemer C, Szwebel TA, Casanova JL. Interferon-ß Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2. J Clin Immunol. 2021 07; 41(5):931-933. PMID: 33763778.
      Citations: 10     Fields:    Translation:Humans
    18. de Prost N, Bastard P, Arrestier R, Fourati S, Mahévas M, Burrel S, Dorgham K, Gorochov G, Tandjaoui-Lambiotte Y, Azzaoui I, Fernandes I, Combes A, Casanova JL, Mekontso-Dessap A, Luyt CE. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia. J Clin Immunol. 2021 04; 41(3):536-544. PMID: 33616813.
      Citations: 17     Fields:    Translation:Humans
    19. Lévy R, Bastard P, Lanternier F, Lecuit M, Zhang SY, Casanova JL. IFN-a2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2. J Clin Immunol. 2021 01; 41(1):26-27. PMID: 33392853.
      Citations: 9     Fields:    Translation:Humans
    20. Lévy R, Bastard P, Lanternier F, Lecuit M, Zhang SY, Casanova JL. Correction to: IFN-a2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2. J Clin Immunol. 2021 Jan; 41(1):28. PMID: 33474625.
      Citations: 3     Fields:    
    21. Zhang Q, Bastard P, Bolze A, Jouanguy E, Zhang SY, Cobat A, Notarangelo LD, Su HC, Abel L, Casanova JL. Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med (N Y). 2020 Dec 18; 1(1):14-20. PMID: 33363283.
      Citations: 28     
    22. Citations: 516     Fields:    Translation:HumansCellsPHPublic Health
    23. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V, Manry J, Shaw E, Haljasmägi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodríguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 10 23; 370(6515). PMID: 32972996.
      Citations: 574     Fields:    Translation:HumansCellsPHPublic Health
    Bastard's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (108)
    Explore
    _
    Co-Authors (529)
    Explore
    _
    Similar People (60)
    Explore
    _